BioLineRx Ltd., a biopharmaceutical company specializing in oncology and rare diseases, has released its unaudited financial results for the second quarter of 2025. The company reported total revenues of $0.3 million for the quarter, attributed to royalties from Ayrmid's commercialization of APHEXDA for stem cell mobilization in the U.S. This marks a significant change from the same period in 2024, when revenues included direct commercial sales by BioLineRx before a transaction with Ayrmid in November 2024. The cost of revenues for the second quarter of 2025 was negligible, in contrast to $0.9 million in the second quarter of 2024, reflecting the same changes in sales channels. BioLineRx's balance sheet as of June 30, 2025, shows $28.2 million, providing a cash runway extended into the first half of 2027, an improvement from previous guidance into the second half of 2026. In terms of business operations, BioLineRx is actively evaluating potential pipeline expansion opportunities, particularly in oncology and rare diseases, with a transaction targeted for 2025. Clinical developments include ongoing enrollment in the CheMo4METPANC Phase 2b trial for motixafortide in combination with cemiplimab and standard chemotherapy, supported by Columbia University, Regeneron, and BioLineRx. An interim analysis is planned upon observing 40% of progression-free survival events.